3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neoplasm Metastasis
4
Neoplasms
3
Melanoma
3
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia
1
Insulin-Like Growth Factor I, Resistance To
1
Humoral Hypercalcemia Of Malignancy
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
94
Radiotherapy
40
Bevacizumab
40
Lomustine
21
Radiation
18
Surgical Procedures, Operative
10
Carboplatin
9
pembrolizumab
8
Nivolumab
8
Carmustine
8
Irinotecan
7
IL13-PE38
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Flucytosine
6
Cyclophosphamide
6
ABT-414
6
vocimagene amiretrorepvec
5
depatuxizumab mafodotin
5
Valacyclovir
5
Drug Therapy
5
veledimex
4
sargramostim
4
enzastaurin
4
NVP-BKM120
4
Gemcitabine
4
Dianhydrogalactitol
4
Chlorotoxin
4
Aminolevulinic Acid
4
verubulin
3
selinexor
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Glioblastoma
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled